Inflammation is a critical pathway in the pathogenesis of atherosclerosis. Previous studies have shown that plasma levels of high-sensitivity C-reactive protein (hsCRP), a marker of inflammation, are associated with cardiovascular disease independent of traditional risk factors. Randomized trial data have also shown that statins reduce not only hsCRP but also cardiovascular event rates independent of their effect on low-density lipoprotein cholesterol (LDL-C) level. More recently, the CANTOS trial showed that directly reducing inflammation with canakinumab, an interleukin (IL)-1β neutralizing monoclonal antibody, could also reduce cardiovascular event rates. These mark the first phase 3 trial results validating inflammation as a viable targ...
The hypothesis of an inflammatory component in the pathogenesis of atherosclerosis has been under in...
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipi...
BACKGROUND Experimental and clinical data suggest that reducing inflammation without affecting lipid...
Inflammation is a critical pathway in the pathogenesis of atherosclerosis. Previous studies have sho...
The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequ...
Atherosclerosis is still a great burden on human health and scientific achievements of the past 30 y...
The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) provides intriguing suppor...
Background Inflammation contributes to all phases of the atherothrombotic process, and patients with...
Atherosclerosis is a chronic inflammatory disorder of the vasculature where cholesterol accumulates ...
Dyslipidaemia and inflammation are closely interconnected in their contribution to atherosclerosis. ...
IL-1 cytokines are mainly responsible for controlling a series of pro-inflammatory reactions induced...
The hypothesis of an inflammatory component in the pathogenesis of atherosclerosis has been under in...
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipi...
BACKGROUND Experimental and clinical data suggest that reducing inflammation without affecting lipid...
Inflammation is a critical pathway in the pathogenesis of atherosclerosis. Previous studies have sho...
The outcomes of the Canakinumab Anti-inflammatory Thrombosis Outcome Study (CANTOS) trial have unequ...
Atherosclerosis is still a great burden on human health and scientific achievements of the past 30 y...
The CANTOS trial (Canakinumab Anti-Inflammatory Thrombosis Outcome Study) provides intriguing suppor...
Background Inflammation contributes to all phases of the atherothrombotic process, and patients with...
Atherosclerosis is a chronic inflammatory disorder of the vasculature where cholesterol accumulates ...
Dyslipidaemia and inflammation are closely interconnected in their contribution to atherosclerosis. ...
IL-1 cytokines are mainly responsible for controlling a series of pro-inflammatory reactions induced...
The hypothesis of an inflammatory component in the pathogenesis of atherosclerosis has been under in...
BACKGROUND: Experimental and clinical data suggest that reducing inflammation without affecting lipi...
BACKGROUND Experimental and clinical data suggest that reducing inflammation without affecting lipid...